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Abstract Spondyloarthritis (SpA) is a family of inflammato-
ry diseases sharing clinical, genetic, and radiological features.
While crucial for tailoring early interventions, validated prog-
nostic biomarkers are scarce in SpA. We analyze the correla-
tion between serum levels of vasoactive intestinal peptide
(VIP) and disease activity/severity in patients with early
chronic inflammatory back pain. The study population com-
prised 54 patients enrolled in our early chronic inflammatory
back pain register. We collected demographic information,
clinical data, laboratory data, and imaging findings. VIP levels
were measured by enzyme immunoassay in serum samples
from 162 visits. The association between independent vari-
ables and VIP levels was analyzed using longitudinal multi-
variate analysis nested by patient and visit. No significant
differences were observed in VIP levels between these two
groups. Lower levels of VIP were significantly associated
with a higher Bath Ankylosing Spondylitis Disease Activity
Index (BASFI) score, presence of bone edema in magnetic
resonance imaging (MRI) scan, and lower hemoglobin levels.
Coexistence of cutaneous psoriasis was independently associ-
ated with lower VIP levels, and similar trend was observed for
enthesitis. We conclude that SpA patients with low serum VIP
levels had worse 2-year disease outcome, suggesting that se-
rum VIP levels could be a valid prognostic biomarker.
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Introduction
Spondyloarthritis (SpA) is a family of interrelated rheu-
matic diseases that share clinical and radiological mani-
festations; the most prevalent and paradigmatic member
of the group is ankylosing spondylitis (Dougados and
Baeten 2011). SpA comprises a wide variety of skeletal
and extra-skeletal phenotypes that are associated with the
presence of the HLA-B27 antigen, which accounts for
familial association and can explain recent hallmark find-
ings on pathogenesis (Colbert et al. 2010). Compared
with joint involvement in rheumatoid arthritis (RA), in-
flammation in SpA mainly takes the form of enthesitis
and commonly results in bone formation and ankylosis
rather than bone erosion (Marzo-Ortega et al. 2002;
McGonagle et al. 2014). Nevertheless, the consequences
of these changes also lead to functional limitations, poor
quality of life, loss of working hours, and even decreased
life expectancy (Braun and Pincus 2002; Fabreguet et al.
2012). Prognosis is often poorer because of the delay in
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diagnosis, especially in patients with isolated axial in-
volvement (Rudwaleit et al. 2005). This was particularly
true until 5–10 years ago, when diagnosis could only be
confirmed based on radiological damage (van der Linden
et al. 1984). New classification criteria enable SpA to be
diagnosed before radiologic evidence of disease is avail-
able (Rudwaleit et al. 2009b), and magnetic resonance
imaging (MRI) now plays a key role in the early identi-
fication of patients with SpA (Bennett et al. 2009).
Nonetheless, diagnosis of non-radiologic SpA remains a
challenge, since, in most cases, the first manifestation is
low back pain, a common complaint in the general pop-
ulation (Carmona et al. 2001; Deyo and Weinstein 2001).
Biologics, mainly TNF blockers, are the second ma-
jor advance in the management of SpA (Machado et al.
2013). However, given the considerable heterogeneity in
the clinical manifestations of these disorders, ranging
from self-limiting to chronic severe and progressive
forms (Dougados and Baeten 2011), and concerns over
safety and cost, the use of TNF blockers should be
restricted to patients with an optimal risk-benefit ratio.
Prognostic markers such as C-reactive protein (CRP)
levels, smoking, HLA-B27 positivity, and structural
damage at diagnosis have been associated with progres-
sion of radiological damage (Chung et al. 2012; Marzo-
Ortega et al. 2009; Poddubnyy et al. 2012); however,
validated biomarkers for predicting progression are lack-
ing and early detection of candidates for TNF blockade
remains difficult.
Vasoactive intestinal peptide (VIP) is a molecule of
the neuroendocrine-immune network with demonstrated
immunoregulatory properties (Gomariz et al. 2006;
Leceta et al. 2007). Treatment with VIP has been shown
to reduce the severity of arthritis in murine models
(Delgado et al. 2001; Juarranz et al. 2005) and improves
the course of other inflammatory models in mice (Abad
et al. 2003; Jimeno et al. 2010; Li et al. 2006; Lodde
et al. 2006). In human assays, in vitro use of VIP regu-
lated differentiation of T cells, modulated the balance of
proinflammatory and anti-inflammatory cytokines
(Gutierrez-Canas et al. 2008), and decreased expression
of several proinflammatory pathways in synovial fibro-
blasts (Carrion et al. 2011, 2014; Gutierrez-Canas et al.
2006). We recently reported that early arthritis patients
with low baseline serum VIP levels have a more severe
disease course and require more intensive treatment with
disease-modifying anti-rheumatic drugs (DMARDs)
(Martinez et al. 2014). In addition, reduced VIP expres-
sion has been observed in the synovial fluid of osteoar-
thritis patients with a poorer disease course (Jiang et al.
2012). The aim of this study, therefore, was to elucidate
the potential role of VIP serum levels as a biomarker of
severity in early inflammatory back pain.
Material and Methods
Ethics Statement
The register protocol for the early chronic inflammatory back
pain (CIBP) clinic at Hospital Universitario La Princesa was
reviewed and approved by the Ethics Committee for Clinical
Research at Instituto de Investigación Sanitaria La Princesa.
Consecutive patients who attended the early CIBP clinic from
June 2010 to June 2013 were recruited. All patients were
informed about the study and signed an informed consent
form before their inclusion in the register.
Patients
The study sample comprised 54 patients from the register. The
inclusion criteria are inflammatory back pain (IBP) for more
than 3 months and less than 2 years, and symptom onset be-
fore age 45 years.
The register protocol comprised three prospective visits
(baseline, 1 and 2 years). The data recorded at baseline include
gender, age, ethnicity, and educational and occupational sta-
tus. At each visit, we systematically collect clinical and labo-
ratory data, as follows: date of onset of IBP, specific features
of SpA (enthesitis, arthritis, uveitis, psoriasis, and inflamma-
tory bowel disease), previous infections and family history of
SpA. Patients were asked to complete the Bath Ankylosing
Spondylitis Disease Activity Index (BASDAI) (Garrett et al.
1994) and Bath Ankylosing Spondylitis Functional Index
(BASFI) (Calin et al. 1994). The laboratory parameters re-
corded include HLA-B27 positivity, CRP levels, erythrocyte
sedimentation rate (ESR), alkaline phosphatase (ALP), and
hemoglobin (Hb) among other parameters. In addition, serum
samples were taken and stored at −80 °C. Radiographs of the
sacroiliac joints and the cervical and lumbar spine (lateral
view) were taken at every visit. Radiological sacroiliitis was
defined according to the modified New York criteria (van der
Linden et al. 1984). MRI of the sacroiliac joints is performed
at baseline to assess the presence of the active inflammatory
lesions (bone marrow edema) according to the Assessment of
SpondyloArthritis international Society (ASAS)/Outcome
Measures in Rheumatology (OMERACT) definition
(Rudwaleit et al. 2009a).
Information related to the treatment established for each
patient (DMARDs, nonsteroidal anti-inflammatory drugs
[NSAIDs], biologic agents, and/or corticosteroids) is also re-
corded. The data were entered into an electronic database.
Of the 54 patients initially enrolled, 37 were diagnosed
with SpA based on the rheumatologist’s clinical judgment,
34 fulfilled the ASAS criteria for SpA (Rudwaleit et al.
2009b) and 13 the New York criteria for ankylosing spondy-
litis (van der Linden et al. 1984). After 2 years of follow-up,
the 17 patients who did not satisfy the criteria for a diagnosis
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of SpAwere considered to have non-specific chronic low back
pain (NLBP).
Measurement of Serum VIP Level
VIP levels were assessed using a commercially available com-
petitive enzyme-linked immunosorbent assay (ELISA) kit
(Phoenix Pharmaceuticals, Karlsruhe, Germany). Briefly, the
serum samples were freeze-dried and dissolved in ELISA
buffer (2:1), added to an immunoplate coated with a second-
ary antibody, and incubated with biotinylated VIP and a pri-
mary antibody whose Fab fragment was competitively bound
by both biotinylated peptide and targeted peptide in samples.
After washes, we added streptavidin-horseradish peroxidase
to each well. During this incubation, the enzyme catalyzed the
oxidation of the substrate solution. We terminated the enzy-
matic reaction using a stop solution and measured absorbance
at 450 nm. A standard curve of known concentration was
established. The concentration of VIP in the samples was de-
termined by extrapolation to this standard curve and applica-
tion of the corresponding dilution factor. Samples from each
patient were assayed twice. The minimum detectable concen-
tration was 0.12 ng/ml, with an intra-assay and interassay
variation of ≤5 and 15%, respectively.We previously reported
that there was no significant correlation between VIP serum
level and frozen time (Martinez et al. 2014).
Statistical Analysis
Normally distributed quantitative variables were represented
as the mean±standard deviation (SD), while non-normally
distributed variables were represented as the median and in-
terquartile range (IQR). Variables with a normal distribution
were analyzed using the t test; variables with a non-normal
distribution were analyzed using the Mann-Whitney test or
Kruskal-Wallis test. Categorical variables were expressed as
percentages and significance levels between groups were
established using the χ2 test or the Fisher exact test.
In order to better determine the association between hetero-
geneity in serum VIP levels and clinical variables, we fitted a
population-averaged model by means of generalized linear
models nested by patient and visit using the xtgee command
of Stata 12 for Windows (StataCorp LP, College Station, TX,
USA). Since the raw variable serum VIP level did not show a
Gaussian distribution, data were normalized through logarith-
mic transformation. Variables displaying a p value <0.15 in
the bivariate analysis were included in the multivariate analy-
sis. Age and sex were included because previous studies had
shown that these variables can act as confounders (Martinez
et al. 2014). In addition, considering the interassay variability
of ELISA, the model was also adjusted for the variations in
assay plate VIP levels. Thereby, the final models were
constructed using the quasi-likelihood under the indepen-
dence model information criterion and the Wald test (Pan
2001) after removing all variables with a p value above 0.15.
Results
Characteristics of Patients with Early SpA
The study population comprised 54 patients with either SpA
(n=37) or NLBP (n=17). Table 1 shows the characteristics of
the patients at baseline. The main differences between the two
groups were that those diagnosed with SpA more often had a
family history of SpA, HLA-B27 positivity, inflammation,
structural damage in the sacroiliac MRI scan or radiographs,
higher PCR levels, and lower levels of hemoglobin than pa-
tients with NLBP. However, no significant differences be-
tween these groups were detected for the functional indices,
disease activity, or other laboratory variables (Table 1).
No significant differences were detected in serum VIP
levels between SpA patients and NLBP patients at baseline
(p=0.36) (Table 1). In addition, no relevant variation in VIP
levels was observed during follow-up in either patient subset.
We observed a non-significant trend toward increased VIP
levels with age (data not shown), as we had reported previ-
ously in RA patients (Martinez et al. 2014). However, we did
not observed significant differences by gender (data not
shown), opposite to what we had observed in RA patients
(Martinez et al. 2014).
Low Serum VIP Levels are Associated with Different
Features of SpA
The BASDAI and BASFI scores were associated with serum
VIP levels in the bivariate analysis, although only BASFI
maintained this association in the multivariate analysis
(Table 2). Patients with lower VIP levels had significantly
higher BASFI scores (Fig. 1a), which indicate more severe
disability. In addition, patients with inflammation on the
MRI scan also had lower serum levels of VIP (Fig. 1b). This
association was significant and independent in the multivari-
ate analysis (Table 2). Furthermore, hemoglobin, which is
associated with disease activity, was also significantly associ-
ated with serum VIP levels (Table 2 and Fig. 1c).
The presence of enthesitis or cutaneous psoriasis was also
independently associated with lower serum VIP levels
(Table 2, Fig. 2).
Only two patients in our study had inflammatory bowel
disease; a non-significant trend toward lower levels of VIP
was observed in both (data not shown). By contrast, patients
who had experienced uveitis displayed significantly higher
levels of VIP (Table 2).
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In order to determine how robust these results were, we
also perform a multivariate analysis restricted to the SpA pa-
tients group. Most associations remain similar as those de-
scribed herein (Table 3).
Finally, only three patients required TNF blockers during
follow-up, and we observed a non-significant trend toward
higher levels of VIP after TNF blockade (data not shown).
No significant association was observed with the prescription
of DMARDs (sulfasalazine and methotrexate).
Discussion
We provide the first evidence of the association between low
serumVIP levels and increased disease severity in patients with
early SpA, namely, impaired functional status, bone edema in
MRI, and a more intense inflammatory burden (anemia, psori-
asis, IBD, and enthesitis). Our results provide additional sup-
port to in vitro and animal models by reinforcing the role of
VIP as a major regulator of the immune system in autoimmune
diseases (Gomariz et al. 2006; Gutierrez-Canas et al. 2008).
Although a previous study had described higher levels of
serum VIP in ankylosing spondilitis patients compared to
healthy donors (Nalbant et al. 2011), our results showed no
differences between SpA and nonspecific low back pain pa-
tients. Possible explanations for this divergence are differ-
ences between both populations in gender distribution, race,
Table 1 Baseline characteristics of patients with spondyloarthritis or chronic low back pain
Spondyloarthritis (n=37) Low back pain (n=17) Total (n=54) p value
Age* (years) 35.8±10.7 40.8±9.7 37.5±10.6 0.09
Gender** (female) 25 (67.6) 8 (47.1) 33 (61) NS
Ethnicity** (Caucasian) 26 (70.3) 12 (70.6) 38 (70.4) NS
Family history of SpA** 14 (37.8) 1 (5.9) 15 (27.8) 0.015
HLA-B27 (+)** 21 (56.7) 3 (17.7) 24 (44.4) 0.007
Enthesitis** 16 (43.2) 3 (17.7) 19 (35.2) 0.067
Arthritis** 11 (29.7) 1 (5.9) 12 (22.2) 0.05
Uveitis** 3 (8.1) 1 (5.9) 4 (7.4) NS
Psoriasis** 4 (10.8) 1 (5.9) 5 (9.3) NS
IBD ** 2 (5.4) 0 (0.0) 2 (3.7) NS
Previous infections** 3 (8.1) 0 (0.0) 3 (5.6) NS
Sacroiliitis MRI** 22 (59.5) 0 (0.0) 22 (40.7) <0.001
Sacroiliitis X-ray** 12 (33.3) 0 (0.0) 12 (22.2) NS
BASDAI* 40.5±23.1 36.4±22.9 39.4±22.7 NS
BASFI*** 29 [12–45] 25.5 [11–50] 26 [12–45] NS
CRP (mg/dl) * 0.99±2.3 0.2±0.25 0.7±0.2 0.048
ESR (mm/h)* 23.3±18.8 15.6±13.0 21.0±17.5 0.082
ALP (U/l)* 62.8±19.4 67.2±18.2 64.2±18.9 NS
Hb (g/dl)* 13.2±2.4 14.6±1.3 13.6±2.2 0.023
VIP (pg/ml)*** 250 [209 – 280] 292 [230–337] 251 [212–303] NS
Data are shown as the mean±standard deviation (SD), frequency n (%), or median and [interquartile range]
IBD inflammatory bowel disease, MRI magnetic resonance imaging, BASDAI Bath Ankylosing Spondylitis Disease Activity Index, BASFI Bath
Ankylosing Spondylitis Functional Index, CRP C-reactive protein, ESR erythrocyte sedimentation rate, ALP alkaline phosphatase, Hb hemoglobin,
VIP vasoactive intestinal peptide, NS non-significant
Statistical significance was established by * Student’s t test, **χ2 or ***Kruskal-Wallis test for a p value <0.05
Table 2 Multivariate analysis of variables associated with VIP serum
levels
β Coeff.±SE CI (95 %) p value
Enthesitis −0.104±0.058 −0.217 to 0.010 0.075
Uveitis 0.383±0.106 0.176 to 0.591 <0.001
Psoriasis −0.227±0.094 −0.411 to −0.044 0.015
Sacroiliitis MRI −0.150±0.057 −0.262 to −0.038 0.009
Biological therapy 0.184±0.118 −0.048 to 0.417 0.120
BASFI −0.003±0.001 −0.005 to −0.001 0.003
Hb (g/dl) 0.031±0.012 0.006 to 0.055 0.014
Results of multivariate analysis performed with data from SpA patients
and NLBP patients. Only variables with p value <0.15 in the respective
bivariate analysis were included. Variables with p value <0.15, in the
respective bivariate analysis, that were not included in the final model
of the multivariate analysis are as follows: age, family history of SpA,
HLA-B27(+), arthritis, CRP, and ESR
β Coeff. β coefficient of Wald test, SE standard error, CI confidence
interval
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selection of controls, and early versus long-term disease stage.
In addition, our findings are consistent with those of our pre-
vious observation that patients with early arthritis and lowVIP
serum levels have a more severe disease course (Martinez
et al. 2014). Although variability in the VIP gene has not been
reported as a genetic trigger of autoimmune disorders, several
findings raise the possibility that once the disease has devel-
oped, low expression of VIP could lead to poorer outcome
(Jiang et al. 2012; Martinez et al. 2014).
One of the various unmet needs in SpA is the availability of
reliable biomarkers both to distinguish inflammatory back
pain from the more prevalent mechanical pain and to deter-
mine prognosis (Almodovar et al. 2014; de Vlam 2010). New
ASAS diagnostic criteria and increased use of MRI have mit-
igated previous diagnostic limitations, although clinicians still
need tools to predict disease activity and progression or to
decide which patients would benefit from biologic therapies.
In this context, measurement of serum VIP levels could be a
useful tool for detecting a subpopulation with a greater func-
tional and inflammatory burden.
Our results raise the question of why BASFI, instead of
BASDAI, was associated with low VIP levels in the multivar-
iate analysis. Each index correlated well with the other, espe-
cially in early disease, although they have the disadvantage of
focusing only on the patient’s perspective (Ward et al. 2013).
Bearing in mind that other objective measures of disease ac-
tivity such as MRI findings or hemoglobin levels were includ-
ed in the multivariate analysis, it can be assumed that
BASDAI did not provide additional information to the statis-
tical model (Kiltz et al. 2012; Machado et al. 2012). In fact, it
is well known that functional limitation at diagnosis is associ-
ated with a worse prognosis of SpA (Landewe et al. 2009).
Therefore, the negative correlation between serum VIP levels
and evolution of BASFI during follow-up is an interesting
finding, since predicting long-term disability remains a chal-
lenge in patients with early SpA.
The association between low serum VIP levels and extra-
articular features of SpA, such as psoriasis and enthesitis, fur-
ther suggests the role of VIP as a biomarker of severity, since
both impair quality of life and increase treatment require-
ments. In addition, VIP levels in the two patients with inflam-
matory low back pain and IBD were below the median VIP
concentration in the whole population, although the difference
Fig. 1 Correlation between VIP serum levels during follow-up and
clinical, radiological, and analytical variables. a Correlation between
serum VIP levels during follow-up and the BASFI score. Data are
shown as the mean value of VIP (normalized by logarithmic
transformation) for each BASFI value adjusted for the other variables
included in the multivariate analysis (solid dot). The figure also shows
the 95 % confidence interval (lines above and below the dot). b
Association between VIP levels and radiological variables. Distribution
of VIP serum levels of the study cohort based on the presence or absence
of lesions associated with spondylitis onMRI. Data are represented as the
interquartile range (p75 upper edge of the box, p25 lower edge, p50
midline), as well as the p90 (line above the box) and p10 (line below
the box) of the serum VIP levels. Dots represent outliers. This figure
illustrates the association between VIP serum levels and MRI findings
shown at Table 2 where statistical significance is reported. c Association
between VIP levels and hemoglobin levels. Data are shown as the mean
value of VIP (normalized by logarithmic transformation) for each value
of hemoglobin (Hb) adjusted for the other variables included in the
multivariate analysis (solid dot) and the 95 % confidence interval (lines
above and below the dot). a, b The values were estimated using the
margins command of Stata 12, following a multivariate analysis for
longitudinal data nested by visit and patient using the xtgee command
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was not statistically significant. Conversely, we found that the
correlation between VIP and uveitis contrasted with the ex-
pected trend. Nevertheless, among patients with uveitis, the
patient with the highest VIP levels did not fulfill the criteria for
SpA. When this patient was excluded, serum VIP levels in
patients with uveitis did not exceed the median concentration
in the whole population.
Drug therapy for controlling axial inflammation after fail-
ure of NSAIDs remains almost restricted to TNF blockers
(van der Heijde et al. 2011); the role of DMARDs in severe
peripheral forms is limited. Consequently, in recent years, one
of the main objectives in the treatment of SpA has been to
identify patients with an optimal safety profile and cost-
benefit ratio for TNF antagonists. An interesting result in our
study was that treatment with anti-TNF agents seemed to in-
crease serum VIP levels. This effect did not reach statistical
significance, probably owing to the small number of patients
requiring this treatment. However, it is noteworthy that we
previously reported the same effect of TNF blockade on serum
VIP levels in patients with RA: the increase was statistically
significant, probably because of the higher number of patients
treated with TNF blockers (Martinez et al. 2014). Several
features point to serum VIP levels as a putative marker of
the need to prescribe TNF blockers, as follows: (a) high
BASFI scores and the presence of enthesitis have been iden-
tified as predictors of response to therapy with these drugs
(Vastesaeger et al. 2011); (b) anemia is associated with inflam-
matory activity in SpA, and improvements in hemoglobin
levels have been reported after anti-TNF treatment (Furst
et al. 2013; Niccoli et al. 2012); (c) low serum VIP levels have
been associated with high BASFI scores and the presence of
enthesitis and anemia; and (d) administration of TNF blockers
increases serum VIP levels. Furthermore, it would be of par-
ticular interest to determine whether the increase in serumVIP
levels reported with TNF blockers is class-specific or is also
observed in autoimmune disorders treated with other biologi-
cal therapies, such as blockade of interleukin (IL)-6 or IL-12
signaling.
Our study is subject to a series of limitations. First, the
sample is small, although the longitudinal design did enable
us to evaluate a considerable number of observations and to
better control individual variations. Second, wewere unable to
detect differences in VIP levels between patients with SpA
and those with NLBP, even when the first visit was analyzed
separately (data not shown). In addition, we have used a
mixed population of patients that were finally diagnosed from
SpA and others with NLBP. However, when patients with
suspicion of SpA are attended for the first time at the clinic
this is the challenge and establishing early a prognosis may be
Fig. 2 Decreased VIP serum levels are associated with clinical
manifestations of enthesitis (a) and psoriasis (b). The figure illustrates
the association between VIP serum levels and these clinical
manifestations shown at Table 2 where statistical significance is
reported. Data are represented as the interquartile range (p75 upper
edge of the box, p25 lower edge, p50 midline), as well as the p90 (line
above the box) and p10 (line below the box) of serum VIP levels. Dots
represent outliers
Table 3 Multivariate analysis of variables associated with VIP serum
levels in patients diagnosed from spondyloarthritis
β Coeff.±SE CI (95 %) p value
Enthesitis −0.133±0.057 −0.245 to 0.020 0.020
Uveitis 0.165±0.112 −0.054 to 0.385 0.140
Psoriasis −0.203±0.094 −0.388 to −0.018 0.032
Sacroiliitis MRI −0.173±0.058 −0.286 to −0.059 0.003
Biological therapy 0.175±0.123 −0.066 to 0.416 0.150
BASFI −0.003±0.001 −0.006 to −0.001 0.017
Hb (g/dl) 0.023±0.013 0.003 to 0.049 0.081
Results of multivariate analysis performed with data from SpA patients.
Only variables with p value <0.15 in the respective bivariate analysis
were included. Variables with p value <0.15, in the respective bivariate
analysis, that were not included in the final model of the multivariate
analysis are as follows: age, family history of SpA, HLA-B27(+), arthri-
tis, CRP, and ESR
β Coeff. β coefficient of Wald test, SE standard error, CI confidence
interval
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helpful despite a definite diagnosis has not been done.
Nevertheless, our results were similar when analyzing the
whole population or only those patients with SpA diagnosis.
In summary, validated biomarkers of the severity of SpA
are scarce and insufficient to properly identify and classify
early SpA patients according to their treatment requirements
and prognosis. Consequently, new validated biomarkers are
needed to achieve these goals. In this framework, the main
finding of our study is that patients with early inflammatory
low back pain and low serum VIP levels experience a higher
inflammatory burden and worse functional outcome during
the first 2 years of their disease course.
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